Effect of silymarin in the prevention of cisplatin nephrotoxicity, a clinical trial study

Journal of Clinical and Diagnostic Research

Volumn 9, Issue 4, 2015, Pages OC11-OC13

  Momeni, Ali ^a   Hajigholami, Ali ^a   Geshnizjani, Shohreh ^a   Kheiri, Soleiman ^a  

^a SHAHREKORD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Malignancy; Prophylaxis; Renal failure

Indexed keywords

CISPLATIN; SILYMARIN;

ADULT; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; UREA NITROGEN BLOOD LEVEL;

RATTUS;

EID: 84926306185     PISSN: 2249782X     EISSN: 0973709X     Source Type: Journal    
DOI: 10.7860/JCDR/2015/12776.5789     Document Type: Article

References (31)

1. Rossi A, Di Maio M, Chiodini P, Rudd RM, Okamoto H, Skarlos DV, et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: The COCIS meta-analysis of individual patient data. Journal of clinical oncology: AM society Clin Oncol. 2012;30(14):1692-98. PubMed PMID: 22473169.
2. Clavel M, Vermorken JB, Cognetti F, Cappelaere P, de Mulder PH, Schornagel JH, et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Annals of oncology: Eur society Med Oncol /ESMO. 1994;5(6):521-26. PubMed PMID: 7522527.
3. Safirstein R, Miller P, Guttenplan JB. Uptake and metabolism of cisplatin by rat kidney. Kidney international. 1984;25(5):753-58. PubMed PMID: 6540826.
4. [4] Luke DR, Vadiei K, Lopez-Berestein G. Role of vascular congestion in cisplatin-induced acute renal failure in the rat. Nephrology, dialysis, transplantation:Eur Dialysis Transplant Assoc - European Renal Association. 1992;7(1):1-7. PubMed PMID: 1316576.
5. Schilsky RL, Anderson T. Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin. Ann Internal Med. 1979;90(6):929-31. PubMed PMID: 375794.
6. Koch Nogueira PC, Hadj-Aissa A, Schell M, Dubourg L, Brunat-Mentigny M, Cochat P. Long-term nephrotoxicity of cisplatin, ifosfamide, and methotrexate in osteosarcoma. Pediatr Nephrol. 1998;12(7):572-75. PubMed PMID: 9761357.
7. Cao L, Joshi P, Sumoza D. Renal salt-wasting syndrome in a patient with cisplatin-induced hyponatremia: case report. AMJ Clin Oncol. 2002;25(4):344-46. PubMed PMID: 12151962.
8. Reece PA, Stafford I, Russell J, Khan M, Gill PG. Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity. J Clin Oncol. 1987;5(2):304-09. PubMed PMID: 3806171.
9. Siegert W, Beyer J, Strohscheer I, Baurmann H, Oettle H, Zingsem J, et al. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: A phase I/II study. The German Testicular Cancer Cooperative Study Group. J clin oncol. 1994;12(6):1223-31. PubMed PMID: 7911158.
10. Portilla D, Li S, Nagothu KK, Megyesi J, Kaissling B, Schnackenberg L, et al. Metabolomic study of cisplatin-induced nephrotoxicity. Kidney int. 2006;69(12):2194-204. PubMed PMID: 16672910.
11. Filipski KK, Loos WJ, Verweij J, Sparreboom A. Interaction of Cisplatin with the human organic cation transporter 2. Clin Cancer Res: An official journal of the American Association for Cancer Research. 2008;14(12):3875-80. PubMed PMID: 18559608.
12. Liu M, Chien CC, Burne-Taney M, Molls RR, Racusen LC, Colvin RB, et al. A pathophysiologic role for T lymphocytes in murine acute cisplatin nephrotoxicity. J Am Society Nephrol: JASN. 2006;17(3):765-74. PubMed PMID: 16481417.
13. Ramesh G, Reeves WB. TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest. 2002;110(6):835-842. PubMed PMID: 12235115. Pubmed Central PMCID: 151130.
14. Stark JJ, Howel SB. Nephrotoxicity of cis-platinum (II) dichlorodiammine. Clin Pharmacol Ther. 1978;23(4):461-66. PubMed PMID: 415836.
15. Schuchter LM, Hensley ML, Meropol NJ, Winer EP, American Society of Clinical Oncology C, Radiotherapy Expert P. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2002;20(12):2895-903. PubMed PMID: 12065567.
16. Dickey DT, Wu YJ, Muldoon LL, Neuwelt EA. Protection against cisplatin induced toxicities by N-acetylcysteine and sodium thiosulfate as assessed at the molecular, cellular, and in vivo levels. J Pharmacol Exp Ther. 2005;314(3):1052-58. PubMed PMID: 15951398.
17. [17] Benoehr P, Krueth P, Bokemeyer C, Grenz A, Osswald H, Hartmann JT. Nephroprotection by theophylline in patients with cisplatin chemotherapy: A randomized, single-blinded, placebo-controlled trial. J Am Society Nephrol: JASN. 2005;16(2):452-58. PubMed PMID: 15590762.
18. Turgut F, Bayrak O, Catal F, Bayrak R, Atmaca AF, Koc A, et al. Antioxidant and protective effects of silymarin on ischemia and reperfusion injury in the kidney tissues of rats. Int urol Nephrol. 2008;40(2):453-60. PubMed PMID: 18368506.
19. Mansour HH, Hafez HF, Fahmy NM. Silymarin modulates Cisplatin-induced oxidative stress and hepatotoxicity in rats. J biochemistry mol biol. 2006;39(6):656-61. PubMed PMID: 17129399.
20. Valenzuela A, Garrido A. Biochemical bases of the pharmacological action of the flavonoid silymarin and of its structural isomer silibinin. Biol Res. 1994;27(2):105-12. PubMed PMID: 8640239.
21. Wen Z, Dumas TE, Schrieber SJ, Hawke RL, Fried MW, Smith PC. Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract. Drug metabolism and disposition: The biological fate of chemicals. Am. Society Pharmacol Exp Ther. 2008;36(1):65-72. PubMed PMID: 17913795
22. De La Puerta R, Martinez E, Bravo L, Ahumada MC. Effect of silymarin on different acute inflammation models and on leukocyte migration. J Pharm Pharmacol. 1996;48(9):968-70. PubMed PMID: 8910865.
23. Brinda BJ, Zhu HJ, Markowitz JS. A sensitive LC-MS/MS assay for the simultaneous analysis of the major active components of silymarin in human plasma. J Chromatography B Analytical Technologies in the Biomedical and Life Sciences. 2012;902:1-9. PubMed PMID: 22766231.
24. Flora K, Hahn M, Rosen H, Benner K. Milk thistle (Silybum marianum) for the therapy of liver disease. Am j gastroen. 1998;93(2):139-43. PubMed PMID: 9468229.
25. Pepping J. Milk thistle: Silybum marianum. J Am Society Health-Syst Pharmacists. 1999;56(12):1195-97. PubMed PMID: 10484652.
26. Karimi G, Ramezani M, Tahoonian Z. Cisplatin nephrotoxicity and protection by milk thistle extract in rats. Evidence-based complement. Altern Med: eCAM. 2005;2(3):383-86. PubMed PMID: 16136217. Pubmed Central PMCID: 1193544.
27. Abdelmeguid NE, Hania N., Abou Zeinab, Noura S. Protavtive Effect of Silymarin on Cisplatin-induced Nephrotoxicity in Rats. Pakistan J Nutr. 2010;9(7):624.
28. Bokemeyer C, Fels LM, Dunn T, Voigt W, Gaedeke J, Schmoll HJ, et al. Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide anti-tumour activity. Brit J Cancer. 1996;74(12):2036-41. PubMed PMID: 8980410. Pubmed Central PMCID: 2074813.
29. Feher J, Lengyel G. Silymarin in the prevention and treatment of liver diseases and primary liver cancer. Curr Pharm Biotechnol. 2012;13(1):210-17. PubMed PMID: 21466434.
30. Asghar Z, Masood Z. Evaluation of antioxidant properties of silymarin and its potential to inhibit peroxyl radicals in vitro. Pakistan J Pharm Sci. 2008;21(3):249-54. PubMed PMID: 18614420.
31. Pradeep K, Mohan CV, Gobianand K, Karthikeyan S. Silymarin modulates the oxidant-antioxidant imbalance during diethylnitrosamine induced oxidative stress in rats. Eur J Pharmacol. 2007;560(2-3):110-16. PubMed PMID: 17300777.